培美曲塞联合卡培他滨治疗复发转移性乳腺癌临床观察  

Clinical Observation of Pemetrexed Combined with Capecitabine in the Treatment of Recurrent and Metastatic Breast Cancer

作　　者：袁晓荣 孟令茹[1] 于焕欣 李利清[1] 曹坤[1] 张巧凤[1] 

机构地区：[1]包头市肿瘤医院肿瘤内科,内蒙古包头014030

出　　处：《肿瘤基础与临床》2015年第5期396-398,共3页journal of basic and clinical oncology

摘　　要：目的观察培美曲塞联合卡培他滨治疗复发转移性乳腺癌的临床疗效和毒副反应。方法 29例复发转移性乳腺癌患者均接受培美曲塞联合卡培他滨治疗,3周重复,所有病例接受2周期以上的化疗,并评价疗效和毒副反应。结果 29例患者的有效率为27.6%,疾病控制率为58.6%。毒副反应主要为胃肠道反应、骨髓抑制、皮疹及手足综合征,患者均可耐受。结论培美曲塞联合卡培他滨治疗复发转移性乳腺癌高效、低毒、可耐受,对蒽环类和紫杉醇类药物无效的患者仍然有效,值得临床推广研究。Objective To investigate the clinical curative effect and toxicities of pemetrexed combined with capecitabine in the treatment of recurrent and metastatic breast cancer. Methods 29 patients with recurrent and metastatic breast cancer received the pemetrexed combined with capecitabine,three weeks were one cycle,All the patients accepted at least 2 cycles of chemotherapy,and the clinical curative effect and toxicities were observed. Re-sults In the 29 patients,the efficient rate was 27. 6%,the disease control rates was 58. 6%. The major toxicities were bone marrow suppression,gastrointestinal reaction,rash and hand-foot syndrome,and could be tolerated. Con-clusion Pemetrexed combined with capecitabine is safe and effect in the treatment of recurrent and metastatic breast cancer.

关 键 词：复发转移性乳腺癌 培美曲塞 卡培他滨 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]